Cases
Regulus Therapeutics Inc. (NASDAQ: RGLS)
Securities Class Action
Overview
Overview
- Date:
- 1/1/2017
- Status:
- Closed/Complete
NEW YORK, February 2, 2017 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all persons or entities who acquired Regulus Therapeutics Inc. (NASDAQ: RGLS) securities between January 21, 2016 and June 27, 2016 (the “Class Period”).
The Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) patients treated with RG-101 were at increased risk of contracting jaundice; (2) consequently, the Company had overstated RG-101’s approval prospects and/or commercial viability; and (3) as a result of the foregoing, Regulus’s public statements were materially false and misleading at all relevant times.
On June 27, 2016, the Company announced that it had received verbal notice from the U.S. Food and Drug Administration (“FDA”) that the FDA had placed RG-101 on clinical hold after a second serious adverse event of jaundice was reported in a patient treated with the drug. On this news, the Company’s share price fell $2.47, or more than 49%, to close at $2.54 on June 28, 2016.
If you purchased or otherwise acquired Regulus securities during the Class Period and suffered a loss or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
The Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) patients treated with RG-101 were at increased risk of contracting jaundice; (2) consequently, the Company had overstated RG-101’s approval prospects and/or commercial viability; and (3) as a result of the foregoing, Regulus’s public statements were materially false and misleading at all relevant times.
On June 27, 2016, the Company announced that it had received verbal notice from the U.S. Food and Drug Administration (“FDA”) that the FDA had placed RG-101 on clinical hold after a second serious adverse event of jaundice was reported in a patient treated with the drug. On this news, the Company’s share price fell $2.47, or more than 49%, to close at $2.54 on June 28, 2016.
If you purchased or otherwise acquired Regulus securities during the Class Period and suffered a loss or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.